Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.51 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.48 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.48 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.45 |
| ▸ | MAPKAPK2 | P49137 | 6/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | RORC | P51449 | 3/20 | 0.43 |
| ▸ | ATR | Q13535 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29491458 | 1.00 | NAMPT (0.51) | NAMPTKCNQ3KCNQ2CYP17A1CA12 | |
| SCHEMBL12186052 | 0.85 | CYP17A1 (0.46) | NAMPTCYP17A1PSMB8MAPKAPK2MAP4K4 | |
| SCHEMBL18654067 | 0.85 | GAA (0.45) | NAMPTKCNQ3KCNQ2CYP17A1MAPKAPK2 | |
| SCHEMBL31129256 | 0.83 | KCNQ3 (0.53) | KCNQ3KCNQ2 | |
| SCHEMBL14155358 | 0.83 | CA1 (0.51) | CA1 | |
| SCHEMBL6609814 | 0.83 | NAMPT (0.52) | NAMPTCYP17A1CA12CA1CA9 | |
| SCHEMBL31378805 | 0.83 | KCNQ3 (0.53) | NAMPTKCNQ3KCNQ2CYP17A1MAPKAPK2 | |
| SCHEMBL30208803 | 0.83 | NAMPT (0.56) | NAMPTKCNQ3KCNQ2CYP17A1CA12 | |
| SCHEMBL376258 | 0.83 | NAMPT (0.56) | NAMPTKCNQ3KCNQ2CYP17A1CA12 | |
| SCHEMBL535403 | 0.83 | KCNQ3 (0.53) | NAMPTKCNQ3KCNQ2CYP17A1MAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010027197-A1 | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family | BRIDGES ALEXANDER JAMES (US) | 2001-10-04 | — | — | US | claimed |
| US-20230339939-A1 | SUBSTITUTED 1H-PYRROLO[3,2-B]PYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2023-10-26 | — | — | US | disclosed |
| US-20230339939-A1 | SUBSTITUTED 1H-PYRROLO[3,2-B]PYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2023-10-26 | — | — | US | disclosed |
| US-20220194940-A1 | HETEROCYCLIC INHIBITORS OF TYROSINE KINASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2022-06-23 | — | — | US | disclosed |
| CN-109843886-B | Bicyclic pyridone lactams and methods of use thereof | 豪夫迈·罗氏有限公司 | 2022-04-19 | — | — | CN | disclosed |
| EP-3526219-B1 | BICYCLIC PYRIDONE LACTAMS AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2021-12-15 | — | — | EP | disclosed |
| US-20210163475-A1 | BICYCLIC PYRIDONE LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-06-03 | — | — | US | disclosed |
| US-10947226-B2 | Bicyclic pyridone lactams and methods of use thereof | GENENTECH, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| WO-2020219906-A1 | HETEROCYCLIC INHIBITORS OF TYROSINE KINASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-10-29 | — | — | WO | disclosed |
| US-20190241565-A1 | BICYCLIC PYRIDONE LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-08-08 | — | — | US | disclosed |
| US-6521620-B1 | Suppressing tumors, especially breast cancers; antiproli-ferative agents; arthritis, vascular restenosis, psoriasis and angiogenesis; extremely low cytotoxicity | WARNER-LAMBERT COMPANY | 2003-02-18 | — | — | US | disclosed |
| US-6455534-B2 | ANTIPROLIVERATIVE, -CARCINOGENIC AND -TUMOR AGENTS; MITOGENESIS-ACTIVATED PROTEIN KINASE INHIBITORS; NONCYTOTOXIC; BINDING WITH HIGH AFFINITY AT THE ADENOSINE TRIPHOSPHATE BINDING SITE OF THE KINASES | WARNER-LAMBERT COMPANY | 2002-09-24 | — | — | US | disclosed |
| US-6313292-B1 | REACTION FROM 5-AMINO-2-FLUOROPYRIDINE; AMINATION, CYCLIZATION, CHLORINATION, SALT FORMATION, DECHLORINATION, DEBLOCKING | WARNER-LAMBERT COMPANY | 2001-11-06 | — | — | US | disclosed |
| US-20010027197-A1 | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family | BRIDGES ALEXANDER JAMES (US) | 2001-10-04 | — | — | US | disclosed |
| US-6265410-B1 | ANTICARCINOGENIC AGENTS | WARNER-LAMBERT COMPANY | 2001-07-24 | — | — | US | disclosed |
| US-6084095-A | INCLUDING 6-AMINO-4-(3-BROMOANILINO)PYRIDO(3,2-D)PYRIMIDINE; 4-(3-BROMOANILINO)-6-METHYLAMINOPYRIDO (3,2-D)PYRIMIDINE; AND 4-(3-BROMOANILINO)-6-METHYLAMINOPYRIDO(3,2-D)PYRIMIDINE; USEFUL IN TREATING PROLIFERATIVE DISEASES SUCH AS CANCER | WARNER-LAMBERT COMPANY (US) | 2000-07-04 | — | — | US | disclosed |
| US-5654307-A | ANTICARCINOGENIC AGENTS, ANTIARTHRITIC AGENT, SKIN DISORDERS | WARNER-LAMBERT COMPANY (US) | 1997-08-05 | — | — | US | disclosed |
| WO-1997026259-A1 | IMPROVED PROCESS FOR PREPARING 4,6-DISUBSTITUTED PYRIDO[3,4-d]PYRIMIDINES | WARNER-LAMBERT COMPANY (US) | 1997-07-24 | — | — | WO | disclosed |
| EP-0742717-A1 | BICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY | WARNER-LAMBERT COMPANY (US) | 1996-11-20 | — | — | EP | disclosed |
| WO-1995019774-A1 | BICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY | WARNER-LAMBERT COMPANY (US) | 1995-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163475-A1 | BICYCLIC PYRIDONE LACTAMS AND METHODS OF USE THEREOF | CYP3A5, C5, PDXK | NAMPT 658/4885KCNQ3 3242/4885KCNQ2 2465/4885 |
| US-20010027197-A1 | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family | EGFR, ERBB2, ERBB3 | NAMPT 2920/4885KCNQ3 4789/4885KCNQ2 4703/4885 |
| US-10947226-B2 | Bicyclic pyridone lactams and methods of use thereof | CYP3A5, C5, PDXK | NAMPT 658/4885KCNQ3 3242/4885KCNQ2 2465/4885 |
| US-20220194940-A1 | HETEROCYCLIC INHIBITORS OF TYROSINE KINASE | ERBB2, ERBB3, EGFR | NAMPT 1162/4885KCNQ3 4772/4885KCNQ2 4775/4885 |
| US-20190241565-A1 | BICYCLIC PYRIDONE LACTAMS AND METHODS OF USE THEREOF | CYP3A5, C5, PDXK | NAMPT 658/4885KCNQ3 3242/4885KCNQ2 2465/4885 |
| US-20230339939-A1 | SUBSTITUTED 1H-PYRROLO[3,2-B]PYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | CYP1B1, CYP4B1, CYP2C19 | NAMPT 422/4885KCNQ3 1565/4885KCNQ2 1027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.